Role of Interleukin-6 in Exercise

A Lifestyle Intervention Study Investigating the Role of Interleukin-6 in the Beneficial Effect of Exercise on Beta-cell Function in Obese People and Patients With Type 2 Diabetes

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01073826

Acronym

Exil-6

Enrollment

Registered

2010-02-23

Start date

2010-02-28

Completion date

2016-06-30

Last updated

2016-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2, Obesity

Brief summary

The purpose of the study is to understand the role of interleukin-6 during physical activity in patients with type 2 diabetes.

Interventions

BEHAVIORALSport

DRUGTocilizumab

DRUGSitagliptin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Obesity group: BMI 30-40 kg/m2, fasting plasma glucose \<6.4 mmol/l. * Diabetes group: Type 2 diabetes according to American Diabetes Association criteria

Exclusion criteria

* Anti-diabetic drug other than metformin * Diabetes duration of more than 5 years * Inflammatory diseases * Current infection * Liver disease (transaminases \>2x upper normal range) * kidney disease (creatinine \>1.5 mg/dl for men and 1.4 mg/dl for women) * pregnancy or breast-feeding, women of child bearing potential not using an acceptable form of contraception * immunosuppressive disease * corticosteroid use * regular non-steroidal antinflammatory drug usage * history of carcinoma * history of tuberculosis * anemia, bleeding disorders * obstructive pulmonary disease.

Design outcomes

Primary

Measure	Time frame
Glucagon like peptide- 1 (GLP-1)	Change in GLP-1 secretion compared to baseline

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026